

AI in MRI Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Clinical Application (Musculoskeletal, Colon, Prostate, Liver, Cardiovascular, Neurology, Lung, Breast, Others), By Offering Type (Hardware, Software, Services), By Technology (Deep Learning, Machine Learning, Computer Vision, NLP, Speech Recognition, Querying Method, Others), By Deployment Type (On-premises and Cloud), By End Use (Hospitals, Clinics, Research & Laboratories, Others), By Region and Competition, 2020-2030F

Market Report | 2025-02-17 | 182 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Multi-User License \$5500.00
- Custom Research License \$8000.00

Report description:

Global AI in MRI Market was valued at USD 5.22 Billion in 2024 and is expected to reach USD 8.24 Billion by 2030 with a CAGR of 7.86% during the forecast period. The global AI in MRI market is being driven by several key factors. Technological advancements in AI algorithms and machine learning models have significantly improved the efficiency and accuracy of MRI imaging. AI-powered systems enable faster image processing, aiding in quicker diagnoses and more accurate readings. The growing demand for personalized medicine and early detection of diseases like cancer and neurological disorders has further accelerated the adoption of AI in MRI. The increasing need to reduce healthcare costs, combined with the pressure for improved patient outcomes, is also fueling market growth. The integration of AI with cloud-based platforms and the rise of healthcare data analytics have enhanced the accessibility and scalability of AI-driven MRI solutions.

Key Market Drivers

Technological Advancements in AI Algorithms and Machine Learning Models

The rapid advancements in artificial intelligence (AI) algorithms and machine learning (ML) models are one of the primary drivers

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

of growth in the global AI in MRI market. In recent years, AI has made significant progress in its ability to interpret complex data, especially in the field of medical imaging. MRI scans, known for their high-resolution and detailed imaging, have traditionally been evaluated by radiologists, but AI systems are now increasingly being used to process and analyze these images with remarkable precision. The capabilities of AI algorithms to improve diagnostic accuracy, reduce human error, and assist in detecting subtle abnormalities in images are contributing significantly to the increasing reliance on AI in the MRI market. In July 2022, the FDA granted Philips SmartSpeed, an AI-based software, its 510(k) approval, allowing it to provide revolutionary high-speed, high-resolution MRI imaging. With its wide compatibility, the software facilitates faster and higher-quality scans for nearly all patients, including those with implants, covering 97% of clinical protocols. Additionally, this advanced MR acceleration software delivers scans up to three times faster, significantly enhancing the efficiency of MR departments while maintaining superior image resolution.

Traditional MRI imaging requires a substantial amount of time for radiologists to assess and interpret the images, especially in cases where there is a large volume of scans to be processed. AI-driven solutions are designed to automate much of this process, providing faster analysis with reduced human intervention. AI models, particularly deep learning neural networks, can be trained to detect patterns in MRI scans, enabling them to identify even the most subtle anomalies, such as early-stage cancers, neurological disorders, or cardiovascular issues. These advancements not only enhance diagnostic accuracy but also allow for earlier detection of medical conditions, which is crucial for improving patient outcomes.

The ability of AI to handle large datasets and integrate with advanced imaging technologies is transforming the way healthcare professionals approach MRI diagnostics. For example, AI tools can be integrated with existing MRI machines, enhancing their capabilities by enabling real-time analysis during scanning procedures. This allows for more efficient workflows, where clinicians can make informed decisions faster. These advancements in AI algorithms not only optimize the MRI process but also reduce the need for repeat scans, leading to reduced costs and enhanced patient care. AI is also playing a vital role in the area of personalized medicine. Personalized healthcare aims to tailor medical treatment to individual patients based on their unique characteristics, such as genetic makeup, lifestyle, and health conditions. AI's ability to analyze vast amounts of patient data, including MRI images, allows for more precise diagnoses and better-targeted treatments. By accurately identifying the extent of diseases and providing insights into how they are progressing, AI tools enable healthcare providers to create individualized treatment plans that optimize patient outcomes.

The constant evolution of machine learning models is also driving the improvement of AI in MRI systems. The more data these systems are exposed to, the more accurate and effective they become over time. As AI models become more sophisticated, their ability to process complex imaging data continues to expand, leading to enhanced diagnostic tools and better decision-making in clinical settings. For instance, deep learning techniques like convolutional neural networks (CNNs) have demonstrated their power in analyzing medical images, improving not only the speed of interpretation but also the precision of results.

Another key advancement in AI is its ability to automate the detection of specific features within MRI scans. In the past, radiologists had to manually identify and measure certain features in images, which could be time-consuming and subjective. However, AI-powered systems can now automatically detect and measure features such as lesions, tumors, and organ abnormalities, providing more consistent results across different cases. This reduces variability in interpretations and ensures that patients receive accurate diagnoses.

As these AI-driven innovations continue to evolve, the potential to enhance MRI diagnostics will only expand. In addition to improving accuracy, speed, and reliability, AI algorithms are also enabling new applications in the field of MRI. For example, AI is being used to assist in multi-modal imaging, where data from various imaging techniques, such as CT scans, PET scans, and MRIs, are integrated to provide a more comprehensive understanding of a patient's condition. These integrated AI tools help clinicians make more informed decisions by combining insights from multiple imaging sources.

Growing Demand for Early Detection and Personalized Medicine

The growing demand for early detection of diseases and the shift toward personalized medicine are significant drivers of the global AI in MRI market. Early diagnosis is critical for improving patient outcomes, especially in the case of complex and life-threatening conditions such as cancer, neurological disorders, and cardiovascular diseases. AI technologies are increasingly being utilized to enhance the ability of MRI systems to detect diseases at their earliest stages, long before they would be detectable through conventional methods. With the power of machine learning algorithms, AI can identify subtle patterns and

anomalies in MRI images that may go unnoticed by the human eye, allowing for earlier intervention.

In the context of cancer, for example, early detection is crucial for improving survival rates. Tumors, especially in their early stages, may be small or have indistinct features, making them difficult to identify on traditional imaging scans. AI systems, particularly those using deep learning techniques, can analyze MRI images in greater detail, detecting these early-stage abnormalities with remarkable accuracy. The ability to detect tumors before they grow larger or spread significantly increases the chances of successful treatment and remission, which is a major contributing factor to the demand for AI-based MRI solutions in oncology. In October 2023, Koninklijke Philips N.V. launched the Philips Image Guided Therapy Mobile C-arm System 3000 (Zenition 30), a new X-ray system that provides real-time image guidance for a wide range of clinical procedures. These include orthopedics, trauma, spine interventions, pain management, and surgical operations, all tailored for use in operating rooms. The demand for personalized medicine also plays a critical role in the growth of AI in the MRI market. Personalized medicine involves tailoring medical treatment to individual patients based on factors such as their genetics, lifestyle, and environment, ensuring that each patient receives the most effective treatment. MRI is a key tool in the diagnostic process, as it provides detailed imaging of organs and tissues, helping physicians understand the severity and progression of diseases. AI's ability to analyze vast datasets, including MRI images, enables healthcare providers to create more precise and individualized treatment plans.

For instance, AI algorithms can assess how a particular patient's disease is progressing by analyzing MRI scans over time, taking into account not only the current state of the disease but also historical imaging data. This allows for a deeper understanding of the disease's behavior and enables more accurate predictions of its future progression. With this information, physicians can offer treatments that are tailored specifically to the patient's condition, increasing the likelihood of a positive outcome.

AI in MRI is also helping to identify patients who may be at risk of developing certain conditions before any clinical symptoms appear. By analyzing patterns in imaging data, AI can identify early warning signs of conditions like Alzheimer's disease, stroke, or cardiac issues, allowing healthcare providers to implement preventive measures or initiate treatment earlier. The shift toward early diagnosis and preventive care is reducing healthcare costs and improving long-term patient outcomes, which is driving the demand for AI-based MRI systems.

In addition, personalized treatment plans are increasingly being powered by AI's ability to integrate and analyze a combination of imaging data, genetic information, and clinical records. This multi-dimensional approach allows healthcare providers to tailor therapies more effectively, taking into account all aspects of the patient's health. AI-driven MRI solutions, therefore, are becoming integral to personalized treatment pathways, enabling more precise and effective interventions. These advancements in AI technology are helping to meet the increasing patient demand for customized care that maximizes treatment effectiveness and minimizes unnecessary side effects.

Rising Healthcare Costs and the Need for Efficiency

As healthcare costs continue to rise globally, there is increasing pressure on healthcare systems to improve operational efficiency while maintaining high standards of care. AI in MRI technology plays a pivotal role in addressing this challenge. By automating complex image analysis, AI-driven MRI solutions can significantly reduce the time required to interpret scans, which helps in streamlining workflows and reducing labor costs. AI systems are capable of detecting abnormalities with greater accuracy and consistency, which can minimize the need for repeat scans and reduce the likelihood of misdiagnoses. With AI improving both the speed and accuracy of diagnostics, healthcare providers can offer faster results to patients, leading to better resource utilization and lower overall costs. The efficiency gains facilitated by AI technology are essential in light of the growing demand for diagnostic imaging and the strain it places on healthcare facilities worldwide.

Rising Incidence of Chronic Diseases and Aging Population

The rising incidence of chronic diseases, such as cancer, cardiovascular diseases, and neurological disorders, along with the growing aging population, is driving the demand for more advanced diagnostic tools like AI-powered MRI systems. A 2020 survey published by Definitive Healthcare revealed that approximately one-third of hospitals and imaging centers utilize AI, machine learning (ML), or deep learning to support tasks related to patient care imaging. Additionally, the growth of this segment is driven by the availability of advanced medical imaging equipment in hospitals with robust infrastructure. As people age, the likelihood of developing complex medical conditions increases, and the need for regular and accurate diagnostic imaging becomes more critical. AI in MRI technology plays a vital role in improving the early detection and monitoring of chronic diseases, enabling

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

healthcare providers to offer timely interventions. For example, AI algorithms can detect early signs of neurodegenerative conditions like Alzheimer's disease, helping physicians implement treatments before symptoms worsen. The growing burden of chronic diseases, coupled with the aging population, is creating a greater demand for AI-driven MRI solutions that offer faster, more accurate, and cost-effective diagnostic capabilities.

Key Market Challenges

Data Privacy and Security Concerns

One of the primary challenges in the Global AI in MRI Market is ensuring data privacy and security. MRI scans and other medical imaging data contain sensitive patient information, and the use of AI to analyze these datasets raises concerns about how this data is handled, stored, and shared. Since AI systems require vast amounts of data to train their algorithms, maintaining patient confidentiality is a significant challenge. In many countries, healthcare data is subject to strict privacy regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States or the General Data Protection Regulation (GDPR) in the European Union. These regulations set stringent requirements for the collection, storage, and sharing of patient information. While AI systems can enhance the efficiency and accuracy of MRI diagnoses, they also raise concerns about potential breaches or misuse of personal data. Protecting sensitive patient data, securing AI algorithms from external threats, and ensuring compliance with privacy regulations are ongoing challenges for the Global AI in MRI Market. As AI continues to evolve and becomes more integrated with cloud-based platforms, safeguarding data during transmission and storage becomes more complex, necessitating advanced cybersecurity measures to protect against data theft, hacking, or accidental exposure.

High Costs of Implementation and Maintenance

The high costs associated with implementing and maintaining AI-driven MRI systems present another challenge for the Global AI in MRI Market. While AI offers significant benefits in terms of efficiency, accuracy, and speed, the upfront investment required to integrate AI technology into existing MRI systems can be prohibitively expensive. Healthcare providers, especially those in developing regions, may struggle with the costs of acquiring the necessary AI software, hardware, and training for their staff. Ongoing maintenance, software updates, and support for AI systems add to the long-term financial burden. Many hospitals and clinics, particularly smaller or resource-constrained ones, may find it difficult to justify these costs, especially when competing priorities demand budget allocations for other medical technologies or infrastructure. Despite the potential for cost savings in the long run through improved diagnostic efficiency and reduced errors, the initial financial outlay and subsequent maintenance costs are significant barriers to widespread adoption of AI in MRI systems.

Lack of Standardization and Regulatory Challenges

Another significant challenge in the Global AI in MRI Market is the lack of standardization and the evolving nature of regulatory frameworks. Unlike traditional MRI machines, which have well-established regulatory processes for their approval and use, AI systems in healthcare are still relatively new and require more comprehensive regulatory oversight. In many regions, AI in healthcare is not yet governed by consistent standards, leading to varying levels of scrutiny and approval processes. Regulatory bodies must address issues such as the validation of AI algorithms, ensuring they meet accuracy and safety standards before being deployed in clinical settings. Without standardization, AI systems may face difficulties in being universally adopted or integrated into existing healthcare infrastructures. As AI technology continues to evolve, regulators are challenged to keep up with rapid developments while ensuring patient safety and the effectiveness of these tools. Until clear, globally accepted standards and regulations are established, the implementation of AI in MRI systems may remain fragmented, hindering growth in the Global AI in MRI Market.

Clinical Adoption and Trust Issues

Despite the potential advantages of AI in MRI, there remains a significant challenge in terms of clinical adoption and the trust that healthcare providers place in these technologies. Many radiologists and clinicians may be hesitant to adopt AI-powered MRI systems due to concerns about the reliability and accuracy of AI-generated results. While AI can assist in image analysis, it is not infallible, and human oversight is still essential to ensure that the diagnoses are correct. There is also apprehension among healthcare professionals regarding the extent to which AI might replace human expertise, leading to fears of job displacement or loss of control over critical decision-making processes. As a result, convincing clinicians to trust AI tools and integrate them into their workflow is a significant hurdle for the Global AI in MRI Market. Building trust in AI requires not only demonstrating its clinical efficacy but also educating healthcare professionals about its role in enhancing, rather than replacing, human expertise.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Market Trends

Improved Diagnostic Accuracy and Reduced Human Error

One of the main advantages of AI in MRI is its ability to improve diagnostic accuracy and reduce human error. Radiologists often face challenges in interpreting complex images due to the high volume of scans they must review and the intricacies of medical imaging. AI algorithms, particularly deep learning models, can analyze MRI scans in great detail, identifying patterns that may be too subtle for human detection. These algorithms are trained using vast datasets of medical images, enabling them to learn and recognize even the slightest abnormalities. This capability ensures that AI-driven MRI systems can assist radiologists in making more accurate diagnoses, reducing the chances of missed or incorrect findings. The reduction of human error is crucial in medical diagnostics, where a single mistake can have severe consequences for a patient's health and treatment outcomes.

Integration of AI with Cloud Computing and Big Data

The integration of AI in MRI with cloud computing and big data analytics is another key driver of market growth. Cloud-based AI systems allow for the secure storage, processing, and sharing of medical imaging data, making it easier for healthcare providers to collaborate and access patient information remotely. A 2020 survey published by Definitive Healthcare revealed that approximately one-third of hospitals and imaging centers utilize AI, machine learning (ML), or deep learning to support tasks related to patient care imaging. Additionally, the growth of this segment is driven by the availability of advanced medical imaging equipment in hospitals with robust infrastructure. This integration enables a more efficient exchange of information across different healthcare facilities and provides healthcare providers with a comprehensive view of a patient's medical history. AI-powered cloud platforms can process large volumes of imaging data quickly, enabling real-time analysis of MRI scans. By utilizing big data analytics, AI systems can identify trends, correlations, and patterns across a vast number of patient cases, leading to more informed decision-making and improved patient outcomes.

Segmental Insights

Clinical Application Insights

Based on the Clinical Application, neurology is currently dominating the Global AI in MRI Market, particularly due to the increasing prevalence of neurological disorders and the critical need for early diagnosis and accurate monitoring. Neurological conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and brain tumors are on the rise globally, contributing to a significant demand for advanced diagnostic technologies like AI-powered MRI systems. AI is particularly effective in neurology as it can detect subtle changes in the brain structure that might go unnoticed by the human eye. The ability to identify early signs of neurological diseases, which often manifest in the form of small changes in brain tissue, has become a game-changer in improving patient outcomes.

MRI plays a central role in diagnosing and monitoring neurological conditions, as it provides detailed imaging of the brain, spinal cord, and other neural structures. However, interpreting MRI scans in neurology can be highly challenging due to the complexity of the brain and the subtlety of certain neurological conditions. AI in MRI is addressing this challenge by providing tools that enhance the diagnostic process. For instance, AI algorithms are trained to recognize patterns in brain images that correspond to early-stage Alzheimer's or Parkinson's disease, allowing for earlier intervention. In many cases, AI has proven more effective than traditional methods in detecting these conditions, which often require a high level of expertise to identify. The adoption of AI in MRI for neurological applications is also driven by its potential to reduce diagnostic time. With the growing global shortage of trained radiologists, AI systems help bridge the gap by automating parts of the diagnostic process. For example, AI can quickly identify and classify abnormalities such as tumors, hemorrhages, or lesions in the brain, significantly speeding up the diagnostic workflow. This speed is crucial in neurology, where early treatment is critical for conditions like stroke, where every minute counts. AI can also improve the accuracy of detecting brain tumors, identifying even small, early-stage tumors that might otherwise be missed by human radiologists.

End Use Insights

Based on the end use segment, hospitals are currently the dominant players. Hospitals account for a significant share of the market due to their extensive use of MRI technology and their need to provide accurate and timely diagnoses for a wide range of medical conditions. Hospitals typically serve as the central hubs for patient care, encompassing various specialties such as neurology, oncology, cardiology, and musculoskeletal disorders, all of which benefit from AI-powered MRI systems. As the demand for faster and more accurate diagnostics increases, hospitals are increasingly adopting AI in MRI to streamline workflows, improve

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

diagnostic accuracy, and enhance patient outcomes.

AI in MRI is particularly beneficial in a hospital setting because of the high patient volume and the complexity of cases that hospitals typically handle. Hospitals are often equipped with advanced MRI machines and are tasked with providing comprehensive diagnostic services, making the need for AI-driven tools to assist radiologists and clinicians essential. With the increasing pressure on healthcare systems to manage large volumes of medical data efficiently, AI plays a critical role in supporting radiologists by automating parts of the diagnostic process, enabling them to focus on more complex cases and interpret results with greater precision.

The integration of AI with MRI technology in hospitals is also driven by the growing need for early detection and personalized medicine. Hospitals are at the forefront of managing chronic diseases, such as cancer, cardiovascular disorders, and neurological conditions, which require early and accurate diagnosis to improve treatment outcomes. AI algorithms, particularly deep learning models, are capable of analyzing MRI scans at a level of detail that can detect abnormalities, such as tumors or lesions, at an earlier stage than traditional methods. In conditions like cancer, early detection is key to successful treatment, and hospitals are increasingly relying on AI to enhance their diagnostic capabilities and offer timely interventions.

Regional Insights

North America was dominating the Global AI in MRI Market. This dominance can be attributed to several key factors, including the region's advanced healthcare infrastructure, high adoption rate of cutting-edge medical technologies, and strong investment in research and development (R&D). The United States, in particular, is at the forefront of the AI in MRI market, driven by its well-established healthcare system and the presence of major healthcare institutions, research universities, and technology companies. These factors have created a robust ecosystem for the development, adoption, and integration of AI technologies in medical imaging.

One of the primary reasons for North America's leadership in the AI in MRI market is its high level of technological innovation and access to capital. The region has a long history of being an early adopter of new medical technologies, and this trend extends to AI applications in healthcare. North American hospitals, research institutions, and diagnostic centers are increasingly integrating AI into their MRI systems to improve diagnostic accuracy, reduce operational costs, and enhance patient outcomes. For instance, AI-driven MRI systems are being utilized to detect early signs of neurological disorders, cancers, and cardiovascular diseases, providing more accurate and timely diagnoses. In the United States, the FDA's (Food and Drug Administration) approval of AI-based medical imaging devices further accelerates the adoption of these technologies by healthcare providers.

The presence of major players in the AI and healthcare industries, including technology giants like IBM, Google, and Microsoft, as well as medical device companies like GE Healthcare, Siemens Healthineers, and Philips, has significantly contributed to North America's dominance in the AI in MRI market. These companies have invested heavily in developing and commercializing AI solutions that enhance MRI diagnostic capabilities. The close collaboration between tech companies and healthcare providers in North America ensures that AI technologies are continuously evolving to meet the needs of clinicians and patients alike.

Key Market Players

- Digital Diagnostics Inc.
- Tempus AI, Inc.
- Advanced Micro Devices, Inc.
- HeartFlow, Inc.
- Enlitic, Inc.
- Viz.ai, Inc.
- EchoNous Inc.
- HeartVista Inc.
- Exo Imaging, Inc.
- Nano-X Imaging Ltd.

Report Scope:

In this report, the Global AI in MRI Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

□□ AI in MRI Market, By Clinical Application:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Musculoskeletal
- o Colon
- o Prostate
- o Liver
- o Cardiovascular
- o Neurology
- o Lung
- o Breast
- o Others

☐☐AI in MRI Market, By Offering Type:

- o Hardware
- o Software
- o Services

☐☐AI in MRI Market, By Technology:

- o Deep Learning
- o Machine Learning
- o Computer Vision
- o NLP
- o Speech Recognition
- o Querying Method
- o Others

☐☐AI in MRI Market, By Deployment Type:

- o On-premises
- o Cloud

☐☐AI in MRI Market, By End Use:

- o Hospitals
- o Clinics
- o Research & Laboratories
- o Others

☐☐AI in MRI Market, By Region:

- o North America
 - ☐ United States
 - ☐ Canada
 - ☐ Mexico
- o Europe
 - ☐ France
 - ☐ United Kingdom
 - ☐ Italy
 - ☐ Germany
 - ☐ Spain
- o Asia-Pacific
 - ☐ China
 - ☐ India
 - ☐ Japan
 - ☐ Australia
 - ☐ South Korea
- o South America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Brazil
- Argentina
- Colombia
- o Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global AI in MRI Market.

Available Customizations:

Global AI in MRI market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

□□ Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validations
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global AI in MRI Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.2. Market Share & Forecast
 - 5.2.1. By Clinical Application (Musculoskeletal, Colon, Prostate, Liver, Cardiovascular, Neurology, Lung, Breast, Others)
 - 5.2.2. By Offering Type (Hardware, Software, Services)
 - 5.2.3. By Technology (Deep Learning, Machine Learning, Computer Vision, NLP, Speech Recognition, Querying Method, Others)
 - 5.2.4. By Deployment Type (On-premises and Cloud)
 - 5.2.5. By End Use (Hospitals, Clinics, Research & Laboratories, Others)
 - 5.2.6. By Region

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.7. By Company (2024)
- 5.3. Market Map
- 6. North America AI in MRI Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Clinical Application
 - 6.2.2. By Offering Type
 - 6.2.3. By Technology
 - 6.2.4. By Deployment Type
 - 6.2.5. By End Use
 - 6.2.6. By Country
 - 6.3. North America: Country Analysis
 - 6.3.1. United States AI in MRI Market Outlook
 - 6.3.1.1. Market Size & Forecast
 - 6.3.1.1.1. By Value
 - 6.3.1.2. Market Share & Forecast
 - 6.3.1.2.1. By Clinical Application
 - 6.3.1.2.2. By Offering Type
 - 6.3.1.2.3. By Technology
 - 6.3.1.2.4. By Deployment Type
 - 6.3.1.2.5. By End Use
 - 6.3.2. Canada AI in MRI Market Outlook
 - 6.3.2.1. Market Size & Forecast
 - 6.3.2.1.1. By Value
 - 6.3.2.2. Market Share & Forecast
 - 6.3.2.2.1. By Clinical Application
 - 6.3.2.2.2. By Offering Type
 - 6.3.2.2.3. By Technology
 - 6.3.2.2.4. By Deployment Type
 - 6.3.2.2.5. By End Use
 - 6.3.3. Mexico AI in MRI Market Outlook
 - 6.3.3.1. Market Size & Forecast
 - 6.3.3.1.1. By Value
 - 6.3.3.2. Market Share & Forecast
 - 6.3.3.2.1. By Clinical Application
 - 6.3.3.2.2. By Offering Type
 - 6.3.3.2.3. By Technology
 - 6.3.3.2.4. By Deployment Type
 - 6.3.3.2.5. By End Use
 - 7. Europe AI in MRI Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Clinical Application
 - 7.2.2. By Offering Type
 - 7.2.3. By Technology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.4. By Deployment Type
- 7.2.5. By End Use
- 7.2.6. By Country
- 7.3. Europe: Country Analysis
 - 7.3.1. Germany AI in MRI Market Outlook
 - 7.3.1.1. Market Size & Forecast
 - 7.3.1.1.1. By Value
 - 7.3.1.2. Market Share & Forecast
 - 7.3.1.2.1. By Clinical Application
 - 7.3.1.2.2. By Offering Type
 - 7.3.1.2.3. By Technology
 - 7.3.1.2.4. By Deployment Type
 - 7.3.1.2.5. By End Use
 - 7.3.2. United Kingdom AI in MRI Market Outlook
 - 7.3.2.1. Market Size & Forecast
 - 7.3.2.1.1. By Value
 - 7.3.2.2. Market Share & Forecast
 - 7.3.2.2.1. By Clinical Application
 - 7.3.2.2.2. By Offering Type
 - 7.3.2.2.3. By Technology
 - 7.3.2.2.4. By Deployment Type
 - 7.3.2.2.5. By End Use
 - 7.3.3. Italy AI in MRI Market Outlook
 - 7.3.3.1. Market Size & Forecast
 - 7.3.3.1.1. By Value
 - 7.3.3.2. Market Share & Forecast
 - 7.3.3.2.1. By Clinical Application
 - 7.3.3.2.2. By Offering Type
 - 7.3.3.2.3. By Technology
 - 7.3.3.2.4. By Deployment Type
 - 7.3.3.2.5. By End Use
 - 7.3.4. France AI in MRI Market Outlook
 - 7.3.4.1. Market Size & Forecast
 - 7.3.4.1.1. By Value
 - 7.3.4.2. Market Share & Forecast
 - 7.3.4.2.1. By Clinical Application
 - 7.3.4.2.2. By Offering Type
 - 7.3.4.2.3. By Technology
 - 7.3.4.2.4. By Deployment Type
 - 7.3.4.2.5. By End Use
 - 7.3.5. Spain AI in MRI Market Outlook
 - 7.3.5.1. Market Size & Forecast
 - 7.3.5.1.1. By Value
 - 7.3.5.2. Market Share & Forecast
 - 7.3.5.2.1. By Clinical Application
 - 7.3.5.2.2. By Offering Type
 - 7.3.5.2.3. By Technology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.5.2.4. By Deployment Type
- 7.3.5.2.5. By End Use
- 8. Asia-Pacific AI in MRI Market Outlook
 - 8.1. Market Size & Forecast
 - 8.1.1. By Value
 - 8.2. Market Share & Forecast
 - 8.2.1. By Clinical Application
 - 8.2.2. By Offering Type
 - 8.2.3. By Technology
 - 8.2.4. By Deployment Type
 - 8.2.5. By End Use
 - 8.2.6. By Country
 - 8.3. Asia-Pacific: Country Analysis
 - 8.3.1. China AI in MRI Market Outlook
 - 8.3.1.1. Market Size & Forecast
 - 8.3.1.1.1. By Value
 - 8.3.1.2. Market Share & Forecast
 - 8.3.1.2.1. By Clinical Application
 - 8.3.1.2.2. By Offering Type
 - 8.3.1.2.3. By Technology
 - 8.3.1.2.4. By Deployment Type
 - 8.3.1.2.5. By End Use
 - 8.3.2. India AI in MRI Market Outlook
 - 8.3.2.1. Market Size & Forecast
 - 8.3.2.1.1. By Value
 - 8.3.2.2. Market Share & Forecast
 - 8.3.2.2.1. By Clinical Application
 - 8.3.2.2.2. By Offering Type
 - 8.3.2.2.3. By Technology
 - 8.3.2.2.4. By Deployment Type
 - 8.3.2.2.5. By End Use
 - 8.3.3. Japan AI in MRI Market Outlook
 - 8.3.3.1. Market Size & Forecast
 - 8.3.3.1.1. By Value
 - 8.3.3.2. Market Share & Forecast
 - 8.3.3.2.1. By Clinical Application
 - 8.3.3.2.2. By Offering Type
 - 8.3.3.2.3. By Technology
 - 8.3.3.2.4. By Deployment Type
 - 8.3.3.2.5. By End Use
 - 8.3.4. South Korea AI in MRI Market Outlook
 - 8.3.4.1. Market Size & Forecast
 - 8.3.4.1.1. By Value
 - 8.3.4.2. Market Share & Forecast
 - 8.3.4.2.1. By Clinical Application
 - 8.3.4.2.2. By Offering Type
 - 8.3.4.2.3. By Technology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.4.2.4. By Deployment Type
- 8.3.4.2.5. By End Use
- 8.3.5. Australia AI in MRI Market Outlook
 - 8.3.5.1. Market Size & Forecast
 - 8.3.5.1.1. By Value
 - 8.3.5.2. Market Share & Forecast
 - 8.3.5.2.1. By Clinical Application
 - 8.3.5.2.2. By Offering Type
 - 8.3.5.2.3. By Technology
 - 8.3.5.2.4. By Deployment Type
 - 8.3.5.2.5. By End Use
- 9. South America AI in MRI Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Clinical Application
 - 9.2.2. By Offering Type
 - 9.2.3. By Technology
 - 9.2.4. By Deployment Type
 - 9.2.5. By End Use
 - 9.2.6. By Country
 - 9.3. South America: Country Analysis
 - 9.3.1. Brazil AI in MRI Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Clinical Application
 - 9.3.1.2.2. By Offering Type
 - 9.3.1.2.3. By Technology
 - 9.3.1.2.4. By Deployment Type
 - 9.3.1.2.5. By End Use
 - 9.3.2. Argentina AI in MRI Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Clinical Application
 - 9.3.2.2.2. By Offering Type
 - 9.3.2.2.3. By Technology
 - 9.3.2.2.4. By Deployment Type
 - 9.3.2.2.5. By End Use
 - 9.3.3. Colombia AI in MRI Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Clinical Application
 - 9.3.3.2.2. By Offering Type
 - 9.3.3.2.3. By Technology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.3.3.2.4. By Deployment Type
- 9.3.3.2.5. By End Use
- 10. Middle East and Africa AI in MRI Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Clinical Application
- 10.2.2. By Offering Type
- 10.2.3. By Technology
- 10.2.4. By Deployment Type
- 10.2.5. By End Use
- 10.2.6. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa AI in MRI Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Clinical Application
- 10.3.1.2.2. By Offering Type
- 10.3.1.2.3. By Technology
- 10.3.1.2.4. By Deployment Type
- 10.3.1.2.5. By End Use
- 10.3.2. Saudi Arabia AI in MRI Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Clinical Application
- 10.3.2.2.2. By Offering Type
- 10.3.2.2.3. By Technology
- 10.3.2.2.4. By Deployment Type
- 10.3.2.2.5. By End Use
- 10.3.3. UAE AI in MRI Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Clinical Application
- 10.3.3.2.2. By Offering Type
- 10.3.3.2.3. By Technology
- 10.3.3.2.4. By Deployment Type
- 10.3.3.2.5. By End Use
- 11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
- 12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13. Porter's Five Forces Analysis
 - 13.1. Competition in the Industry
 - 13.2. Potential of New Entrants
 - 13.3. Power of Suppliers
 - 13.4. Power of Customers
 - 13.5. Threat of Substitute Products
- 14. Competitive Landscape
 - 14.1. Digital Diagnostics Inc.
 - 14.1.1. Business Overview
 - 14.1.2. Company Snapshot
 - 14.1.3. Products & Services
 - 14.1.4. Financials (As Reported)
 - 14.1.5. Recent Developments
 - 14.1.6. Key Personnel Details
 - 14.1.7. SWOT Analysis
 - 14.2. Tempus AI, Inc.
 - 14.3. Advanced Micro Devices, Inc.
 - 14.4. HeartFlow, Inc.
 - 14.5. Enlitic, Inc.
 - 14.6. Viz.ai, Inc.
 - 14.7. EchoNous Inc.
 - 14.8. HeartVista Inc.
 - 14.9. Exo Imaging, Inc.
 - 14.10. Nano-X Imaging Ltd.
- 15. Strategic Recommendations
- 16. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**AI in MRI Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
Segmented By Clinical Application (Musculoskeletal, Colon, Prostate, Liver,
Cardiovascular, Neurology, Lung, Breast, Others), By Offering Type (Hardware,
Software, Services), By Technology (Deep Learning, Machine Learning, Computer
Vision, NLP, Speech Recognition, Querying Method, Others), By Deployment Type
(On-premises and Cloud), By End Use (Hospitals, Clinics, Research & Laboratories,
Others), By Region and Competition, 2020-2030F**

Market Report | 2025-02-17 | 182 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Multi-User License	\$5500.00
	Custom Research License	\$8000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-11"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com